A New Protocol for Continuous Vancomycin Infusion Dosing.

Evaluation of a New Clinical Protocol for Dose Selection of Vancomycin for Continuous Infusion in ICU Patients.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05143645

Acronym

CVIP

Enrollment

101

Registered

2021-12-03

Start date

2013-09-01

Completion date

2020-03-31

Last updated

2021-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, Vancomycin Treatment

Brief summary

This observational study prospectively collect data on chosen dosing, renal function, measured plasma concentrations and adherence to the recommended clinical protocl for ICU patients treated with continuous vancomycin infusion.

Interventions

OTHERPlasma vancoymcin measurements

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

\- Start of continuous vancomycin infusion during the course of intensive care and at least one measurement of plasma concentration.

Exclusion criteria

* Vancomycin treatment within 96 h before admission to the unit. * Vancomycin treatment started with intermittent bolus infusions.

Design outcomes

Primary

Measure	Time frame	Description
Time (days) from start of treatment to first measurement of a plasma vancomycin concentration between 20 and 25 mg/mL	Until the end of treatment or discharge from unit	The title is a full description.
Relationship between time to intended concentration (15-20 mg/L) and adherence to the dosing protocol (% complete adherence).	Until the end of treatment or discharge from unit	For each patient the actually administired dose of vancomycin will be compared to the recommendation in the dosing protocol. The time to the intended concentration will be compared between patients with 100% adherence to the recommendations and for patients with dosing not following the recommendations.

Secondary

Measure	Time frame	Description
Percentage of the total treatment duration with the intended plasma concentration 15-20 mg/L.	Until the end of treatment or discharge from unit	The title is a full description.
Relationship between Percentage of the total treatment duration with the intended plasma concentration (15-20 mg/L) and adherence to the dosing protocol.	Until the end of treatment or discharge from unit	The title in combination with the description of outcome 2 is a sufficient description.

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026